These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17565155)

  • 21. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha.
    Kim WY; Oh SH; Woo JK; Hong WK; Lee HY
    Cancer Res; 2009 Feb; 69(4):1624-32. PubMed ID: 19176399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor effects of deguelin on H460 human lung cancer cells in vitro and in vivo: Roles of apoptotic cell death and H460 tumor xenografts model.
    Hsu YC; Chiang JH; Yu CS; Hsia TC; Wu RS; Lien JC; Lai KC; Yu FS; Chung JG
    Environ Toxicol; 2017 Jan; 32(1):84-98. PubMed ID: 26592500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer.
    Nguyen CT; Thanh La M; Ann J; Nam G; Park HJ; Min Park J; Kim YJ; Young Kim J; Hong Seo J; Lee J
    Bioorg Med Chem Lett; 2021 Aug; 45():128134. PubMed ID: 34044120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth.
    Lang SA; Moser C; Gaumann A; Klein D; Glockzin G; Popp FC; Dahlke MH; Piso P; Schlitt HJ; Geissler EK; Stoeltzing O
    Clin Cancer Res; 2007 Nov; 13(21):6459-68. PubMed ID: 17975158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha.
    Liu YV; Baek JH; Zhang H; Diez R; Cole RN; Semenza GL
    Mol Cell; 2007 Jan; 25(2):207-17. PubMed ID: 17244529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo.
    Zhang PC; Liu X; Li MM; Ma YY; Sun HT; Tian XY; Wang Y; Liu M; Fu LS; Wang YF; Chen HY; Liu Z
    Biochem Pharmacol; 2020 Feb; 172():113771. PubMed ID: 31863779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation.
    Zhou J; Schmid T; Frank R; Brüne B
    J Biol Chem; 2004 Apr; 279(14):13506-13. PubMed ID: 14726529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wogonin inhibits tumor angiogenesis via degradation of HIF-1α protein.
    Song X; Yao J; Wang F; Zhou M; Zhou Y; Wang H; Wei L; Zhao L; Li Z; Lu N; Guo Q
    Toxicol Appl Pharmacol; 2013 Sep; 271(2):144-55. PubMed ID: 23707765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3.
    Nagaraju GP; Park W; Wen J; Mahaseth H; Landry J; Farris AB; Willingham F; Sullivan PS; Proia DA; El-Hariry I; Taliaferro-Smith L; Diaz R; El-Rayes BF
    Angiogenesis; 2013 Oct; 16(4):903-17. PubMed ID: 23838996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
    Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ
    Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer.
    Nagaraju GP; Zakka KM; Landry JC; Shaib WL; Lesinski GB; El-Rayes BF
    Int J Cancer; 2019 Sep; 145(6):1529-1537. PubMed ID: 30801702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells.
    Chun KH; Kosmeder JW; Sun S; Pezzuto JM; Lotan R; Hong WK; Lee HY
    J Natl Cancer Inst; 2003 Feb; 95(4):291-302. PubMed ID: 12591985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deguelin inhibits human hepatocellular carcinoma by antiangiogenesis and apoptosis.
    Lee JH; Lee DH; Lee HS; Choi JS; Kim KW; Hong SS
    Oncol Rep; 2008 Jul; 20(1):129-34. PubMed ID: 18575727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer.
    Hyun SY; Le HT; Nguyen CT; Yong YS; Boo HJ; Lee HJ; Lee JS; Min HY; Ann J; Chen J; Park HJ; Lee J; Lee HY
    Sci Rep; 2018 Sep; 8(1):13924. PubMed ID: 30224681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90.
    Trisciuoglio D; Gabellini C; Desideri M; Ziparo E; Zupi G; Del Bufalo D
    PLoS One; 2010 Jul; 5(7):e11772. PubMed ID: 20668552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
    Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O
    Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia-mediated retinal neovascularization and vascular leakage in diabetic retina is suppressed by HIF-1α destabilization by SH-1242 and SH-1280, novel hsp90 inhibitors.
    Jo DH; An H; Chang DJ; Baek YY; Cho CS; Jun HO; Park SJ; Kim JH; Lee HY; Kim KW; Lee J; Park HJ; Kim YM; Suh YG; Kim JH
    J Mol Med (Berl); 2014 Oct; 92(10):1083-92. PubMed ID: 24875598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization.
    Gao F; Yu X; Li M; Zhou L; Liu W; Li W; Liu H
    Cell Death Dis; 2020 Feb; 11(2):143. PubMed ID: 32081857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.
    Chandarlapaty S; Scaltriti M; Angelini P; Ye Q; Guzman M; Hudis CA; Norton L; Solit DB; Arribas J; Baselga J; Rosen N
    Oncogene; 2010 Jan; 29(3):325-34. PubMed ID: 19855434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.